Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
WCDT-MCRPC
Genomic Characterization of Metastatic Castration Resistant Prostate Cancer
9 awards paid to create it · 43 awards funded work that used it
1. Awards that paid to create this data (6 of 9)
- Cancer Center Administration · ALEX MACDONALD, SELWYN M VICKERS · FY1985–2026
- Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress · Massimo Loda, Steven P. Balk · FY2003–2017
- Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibi… · Brett Stewart Carver, Yu Chen · FY2001–2026
- Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Um… · Martin Edwin Gleave, RUTH D ETZIONI · FY2002–2026
- Michigan Prostate SPORE 2025-2030 · ARUL M CHINNAIYAN, Ganesh S Palapattu · FY2014–2026
- Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resista… · Himisha Beltran, David S. Rickman · FY2017–2021
The best connected are shown.
2. The dataset
3. Articles that used it (6 of 9)
- Su et al. · Cancer cell · 2019186 citations
- Lundberg et al. · Cancer research · 202391 citations
- Guo et al. · Nature communications · 202175 citations
- Franceschini et al. · Cancer discovery · 202465 citations
- Sjöström et al. · Cancer research · 202265 citations
- Lim et al. · Nature communications · 202156 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 43)
- Androgen Receptor Action in Castration Resistant Prostate Cancer · Steven P. Balk, PETER S NELSON · FY2013–2026funded 2 of these 9 articles
- Leadership, Planning and Evaluation · Alan Ashworth, Charles Scott Craik · FY1999–2026funded 2 of these 9 articles
- Integrated Cancer Biology Program · Wolf-Dietrich Heyer, KIT S LAM · FY2002–2026funded 2 of these 9 articles
- Michigan Prostate SPORE 2025-2030 · ARUL M CHINNAIYAN, Ganesh S Palapattu · FY2014–2026funded 2 of these 9 articles · also paid to create this data
- Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Thera… · Felix Yi-Chung Feng, Nupam P Mahajan · FY2019–2023funded 2 of these 9 articles
- Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Um… · Martin Edwin Gleave, RUTH D ETZIONI · FY2002–2026funded 3 of these 9 articles · also paid to create this data
The best connected are shown.
Direct evidence: the award is on the paper, or the accession is in the articleWeaker: infrastructure support, or use declared but not shownHover any card to follow its chain
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| P30CA008748 P30FY1985–2026$715.7M | Cancer Center Administration | API2 |
| P50CA090381 P50FY2003–2017$56.5M | Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress | API2 |
| P50CA092629 P50FY2001–2026$102.6M | Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer | API2 |
| P50CA097186 P50FY2002–2026$98.8M | Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS) | API2 |
| P50CA186786 P50FY2014–2026$50.7M | Michigan Prostate SPORE 2025-2030 | API2 |
| P50CA211024 P50FY2017–2021$21.4M | Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer | API2 |
| R01CA125612 R01FY2007–2017$3.4M | Towards Understanding Prostate Cancer Heterogeneity | API |
| R01CA155169 R01FY2012–2022$3.8M | Understanding Resistance to Next Generation Antiandrogens | API |
| U54CA224079 U54FY2017–2021$13.6M | Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy | API2 |
Awards that funded work using this data
9 of 10 traced articles report an NCI award. 7 of these awards also paid to create the data - the same team publishing again on its own cohort, not a duplicated row.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| P01CA094060 P01FY2002–2018$67.5M | TGF&, PI3K and HER2 Pathways in Breast Cancer Metastasis | API | |
| P50CA092629 P50FY2001–2026$102.6M | Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer | API2 | |
| P50CA140388 P50FY2009–2022$46.7M | Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE | API | |
| R00CA194289 R00FY2018–2020$702k | MDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration Resistance | API | |
| T32CA108462 T32FY2004–2024$10.4M | Molecular and Cellular Mechanisms in Cancer | API | |
| P30CA008748 P30FY1985–2026$715.7M | Cancer Center Administration | API2 | |
| P30CA016672 P30FY1985–2026$543.8M | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | API | |
| R35CA197566 R35FY2016–2022$6.7M | Mechanisms governing metastatic dormancy and reactivation | API | |
| K99CA135592 K99FY2008–2009$195k | Androgen Receptor Regulation by Phosphorylation | API | |
| P50CA090381 P50FY2003–2017$56.5M | Gleason-based mRNA and Metabolomic Profiling to Predict Prostate Cancer Progress | API2 | |
| R00CA135592 R00FY2011–2013$710k | Androgen Receptor Regulation by Phosphorylation | API | |
| R01CA193910 R01FY2015–2019$3.1M | Defining the epigenetic landscape in human prostate cancer | API | |
| R01CA251555 R01FY2021–2025$3.4M | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | API | |
| U54CA156732 U54FY2010–2026$49.8M | The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research | API | |
| R01CA129933 R01FY2008–2026$7.5M | Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells | API | |
| R01CA259007 R01FY2022–2025$3.0M | Blood-based monitoring of bladder-sparing trimodality therapy for muscle-invasive bladder cancer | API | |
| U01CA268933 U01FY2022–2026$3.0M | Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer | API | |
| P01CA163227 P01FY2013–2026$44.6M | Androgen Receptor Action in Castration Resistant Prostate Cancer | API | |
| P30CA082103 P30FY1999–2026$352.4M | Leadership, Planning and Evaluation | API | |
| P30CA093373 P30FY2002–2026$129.0M | Integrated Cancer Biology Program | API | |
| P50CA186786 P50FY2014–2026$50.7M | Michigan Prostate SPORE 2025-2030 | API2 | |
| R01CA227025 R01FY2019–2023$2.8M | Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies | API | |
| R01CA230516 R01FY2018–2022$2.7M | DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications | API | |
| R01CA251245 R01FY2020–2024$1.9M | Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition | API | |
| U01CA224044 U01FY2019–2023$5.1M | Patient-Derived Models of Prostate Cancer for Personalized Medicine | API | |
| P50CA211024 P50FY2017–2021$21.4M | Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer | API2 | |
| R01CA266452 R01FY2022–2026$2.0M | Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage Plasticity | API | |
| R37CA241486 R37FY2020–2026$4.1M | Molecular mechanisms underlying lineage plasticity in prostate cancer | API | |
| U54CA224079 U54FY2017–2021$13.6M | Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy | API2 | |
| K08CA226348 K08FY2018–2022$1.3M | Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate Oncogenesis | API | |
| P30CA016042 P30FY1985–2026$275.5M | Cancer Center Administration (Admin) | API | |
| R01CA208258 R01FY2017–2021$1.7M | Targeting a Novel Epigenetic Signaling Nexus ACK1-pY88H4-AR/AR-V7 in Drug Resistant Metastatic Prostate Cancer | API | |
| U01CA214194 U01FY2016–2021$2.5M | Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer | API | |
| P30CA015704 P30FY1985–2026$556.5M | Prostate Cancer | API | |
| R01CA234715 R01FY2020–2024$2.0M | Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate Cancer | API | |
| P50CA097186 P50FY2002–2026$98.8M | Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS) | API2 | |
| P50CA180995 P50FY2015–2025$40.1M | Biospecimen Core | API | |
| R01CA174777 R01FY2013–2026$4.9M | AR Gene Rearrangements and AR Signaling in Prostate Cancer | API | |
| R01CA208257 R01FY2017–2022$1.8M | The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer | API | |
| R01CA244599 R01FY2020$386k | mRNA Polyadenylation in Prostate Cancer | API | |
| F31CA260920 F31FY2021–2023$98k | Elucidating the role of somatic 3’UTR mutations in prostate cancer pathogenesis | API | |
| R35CA231989 R35FY2018–2024$6.3M | The MYC Transcription Factor Network and the Path to Cancer | API | |
| R37CA230617 R37FY2019–2025$3.1M | Hormone signaling and translation control in advanced prostate cancer | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P01CA094060 P01FY2002–2018$67.5M | TGF&, PI3K and HER2 Pathways in Breast Cancer Metastasis | API |
| P01CA163227 P01FY2013–2026$44.6M | Androgen Receptor Action in Castration Resistant Prostate Cancer | API |
| P30CA015704 P30FY1985–2026$556.5M | Prostate Cancer | API |
| P30CA016042 P30FY1985–2026$275.5M | Cancer Center Administration (Admin) | API |
| P30CA016672 P30FY1985–2026$543.8M | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | API |
| P30CA082103 P30FY1999–2026$352.4M | Leadership, Planning and Evaluation | API |
| P30CA093373 P30FY2002–2026$129.0M | Integrated Cancer Biology Program | API |
| P50CA140388 P50FY2009–2022$46.7M | Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE | API |
| P50CA180995 P50FY2015–2025$40.1M | Biospecimen Core | API |
| U01CA214194 U01FY2016–2021$2.5M | Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer | API |
| U01CA224044 U01FY2019–2023$5.1M | Patient-Derived Models of Prostate Cancer for Personalized Medicine | API |
| U01CA268933 U01FY2022–2026$3.0M | Microfluidic isolation and molecular analysis of circulating tumor cells for the study of neuroendocrine transdifferentiation in prostate cancer | API |
| U54CA156732 U54FY2010–2026$49.8M | The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.